探索胺基金基皮科普拉丁的结构-活性关系 (IV) 产药
Martijn Dijkstra1,2, Hemma Schueffl3, Barbora Adamova3
1Faculty of Chemistry, Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, 1090 Vienna, Austria.
Inorganic chemistry
|January 29, 2025
概括
合成了新的 (II) 和 (IV) 前药,以改善癌症治疗. 胺结合增强了瘤积累,但只有一些衍生品显示出显著的瘤生长抑制,这表明重的配体可能会阻碍白金 (IV) 前药激活.
科学领域:
- 药用化学 医学化学
- 癌症治疗方法 癌症治疗方法
- 药物运输 药物运输 药物运输
背景情况:
- (II) 复合物是标准的癌症治疗方法,但面临着副作用和耐药性的挑战.
- 皮科普拉丁是一种类型,是为了克服谷氨诱导的耐药性而开发的.
- 皮科普拉丁前药和瘤向策略的抗癌潜力在很大程度上仍未被探索.
研究的目的:
- 合成新的皮科普拉丁 (II) 衍生物及其 (IV) 前药物.
- 为了评估蛋白向金 (IV) 前药的合成和特性.
- 评估这些新复合物的体外和体内抗癌疗效.
主要方法:
- 合成皮科普拉丁 (II) 衍生物和 (IV) 预制药,其中含有氧酸盐,循环布坦二碳酸盐,蛋白向性马莱胺或苏胺部分.
- 评估反应动力学与谷氨 (GSH) 和减少与酸.
- 在体外细胞毒性测定 (MTT) 和使用CT26瘤携带小鼠的体内研究.
主要成果:
- 皮科普拉丁衍生物与西斯普拉丁,碳普拉丁和氧沙普拉丁相比,与GSH的反应较慢.
- (IV) 前药的稳定性各不相同,皮科普拉丁 (IV) 非常不稳定.
- 专结合 (IV) 复合物在小鼠中证明了延长血液循环和增强瘤积累.
- 马莱胺功能化的皮科卡博 (PicoCarbo) 和皮科普拉丁 (Picoplatin) 显著抑制了瘤生长,而其他前药在很大程度上是无效的.
结论:
- 蛋白向策略可以增强金前药的瘤积累.
- 皮科普拉丁中的重的2 - 皮科林连接体可能会阻碍 (IV) 前药的激活,当与专结合时.
- 需要进行进一步的研究,以优化基于皮科普拉丁的白金 (IV) 前药,以提高抗癌疗效.
相关概念视频
Drug Distribution: Plasma Protein Binding
4.8K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
4.8K
Prodrugs
2.4K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.4K
Structure-Activity Relationships and Drug Design
493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493
Drug Distribution: Tissue Binding
2.5K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.5K
Drug Metabolism: Phase II Reactions
3.6K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.6K
Protein-Drug Binding: Mechanism and Kinetics
268
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
268


